Priyanka Shah - Kinnate Biopharma VP Communications

KNTEDelisted Stock  USD 2.96  0.27  8.36%   

Insider

Priyanka Shah is VP Communications of Kinnate Biopharma
Phone858 299 4699
Webhttps://www.kinnate.com

Kinnate Biopharma Management Efficiency

The company has return on total asset (ROA) of (0.3363) % which means that it has lost $0.3363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.558) %, meaning that it created substantial loss on money invested by shareholders. Kinnate Biopharma's management efficiency ratios could be used to measure how well Kinnate Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.
Kinnate Biopharma currently holds 3.17 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Kinnate Biopharma has a current ratio of 22.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Kinnate Biopharma's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Filip MDMonte Rosa Therapeutics
50
FACC MDStoke Therapeutics
61
Michael WolfeKezar Life Sciences
N/A
Joo MDDesign Therapeutics
61
Noreen MDKezar Life Sciences
59
Sharon TownsonMonte Rosa Therapeutics
49
Nancy RuizLarimar Therapeutics
N/A
Tracy ZimmermannGeneration Bio Co
54
Jasbir SeehraKeros Therapeutics
68
Joshua KazamKronos Bio
47
Eric RojasStoke Therapeutics
N/A
Edith MDBolt Biotherapeutics
67
Luis BorgesCentury Therapeutics
62
BCh BMKronos Bio
40
Robert KotinGeneration Bio Co
68
David MDErasca Inc
40
Shane WilliamsCentury Therapeutics
N/A
Behrad DerakhshanEdgewise Therapeutics
44
Michael DiemCentury Therapeutics
53
Kenneth JDCentury Therapeutics
N/A
Ronald DundoreWindtree Therapeutics
69
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC. Kinnate Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people. Kinnate Biopharma (KNTE) is traded on NASDAQ Exchange in USA and employs 84 people.

Management Performance

Kinnate Biopharma Leadership Team

Elected by the shareholders, the Kinnate Biopharma's board of directors comprises two types of representatives: Kinnate Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kinnate. The board's role is to monitor Kinnate Biopharma's management team and ensure that shareholders' interests are well served. Kinnate Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kinnate Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert Kania, Senior Research
Richard MBBS, Chief Officer
Jason MD, VP Quality
Neha Krishnamohan, Principal CFO
Barbara Warren, VP Culture
Mark Meltz, General COO
Nima MBA, CEO President
Priyanka Shah, VP Communications

Kinnate Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kinnate Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Consideration for investing in Kinnate Stock

If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Global Correlations
Find global opportunities by holding instruments from different markets
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum